Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $2.781 million which missed the analyst consensus estimate of $15.506 million by 82.07 percent. This is a 95.41 percent decrease over sales of $60.647 million the same period last year.